Trial reportJournal of cachexia, sarcopenia and muscle2025
Postinactivity Exercise Training Improves Sarcopenia Traits in 40-60-Year-Old Women Regardless of Fortified Milk Supplementation.
Trial report in Journal of cachexia, sarcopenia and muscle, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Postinactivity Exercise Training Improves Sarcopenia Traits in 40-60-Year-Old Women Regardless of Fortified Milk Supplementation.Journal of cachexia, sarcopenia and muscle · 2025Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe term sarcopenia was introduced to describe the age-related decline in muscle mass, but current definitions also include measures of muscle strength and function. Menopause increases sarcopenia risk and may exacerbate the adverse effects of physical inactivity. Exercise training is a potent stimulus to restore muscle health, and nutritional supplementation can further improve the outcomes. The purposes of this study were to examine the changes in a set of sarcopenia-related phenotypes induced by a 14-day step-reduction period followed by a 12-week exercise training programme, with or without fortified milk supplementation in healthy 40-60-year-old females, and to determine whether menopausal status interacted with these changes.
methodsIn this double-blind, placebo-controlled randomized trial, females aged 40-60 years were evaluated before and after 2 weeks of reduced activity monitored through pedometer and after a subsequent 12-week exercise + nutrition programme with ingestion of a fortified milk product (FMP) or placebo. Muscle volume (dual-energy X-ray absorptiometry [DXA] and peripheral quantitative computed tomography), handgrip (hydraulic handheld dynamometer), knee extensor and plantar flexor strength (isokinetic dynamometer) and a variety of physical function measures were assessed at all timepoints.
resultsEighty-three self-reported healthy females (50.7 ± 5.3 years; 52 postmenopausal) completed the reduced-activity period, and 67 completed the subsequent exercise training + nutrition phase. At baseline, participants averaged 8323 ± 3077 daily steps and then decreased to 1876 ± 729 during the reduced-activity period. Mean sarcopenia outcomes declined after 2 weeks of activity restriction, with significant changes (p < 0.05) in shank muscle cross-sectional area (CSA) (67.7 ± 9.9 to 66.5 ± 9.9 cm
conclusionsTwo weeks of step reduction negatively affected muscle mass, strength and physical function in 40-60-year-old females. A 12-week training programme including strength exercises and dietary supplementation not only recovered muscular health but also promoted improvements above the baseline before the physical activity restriction. Menopause status did not influence changes in response to step reduction or exercise, and the addition of a fortified milk product during the training period did not influence the induced adaptations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.